Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...
The phase 3 POTOMAC trial tested durvalumab added to BCG in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback